Overview of the Stock Offering#
Cytokinetics, Incorporated, based in South San Francisco, has announced a public offering of approximately 9.86 million shares of common stock, priced at $71.00 per share. This move is expected to generate around $700 million in gross proceeds before accounting for costs related to underwriting and other expenses. The offering is set to close on Friday, pending standard closing conditions.
Company Performance and Stock Valuation#
The announcement comes as Cytokinetics' stock is trading close to its 52-week high, having delivered a remarkable 127% return over the past year. However, some analysts suggest that the stock may currently be overvalued based on its fair value assessment.
Underwriters and Additional Shares#
Cytokinetics has granted underwriters a 30-day option to buy up to about 1.48 million additional shares at the same offering price, minus underwriting fees. The main underwriters for this offering include Morgan Stanley, Goldman Sachs & Co. LLC, J.P. Morgan, and Jefferies, with Mizuho serving as the lead co-manager.
Recent Financial Highlights#
In its recent earnings report, Cytokinetics revealed a significant increase in revenue for Q1 2026, reaching $19.4 million, which is well above analyst expectations of $8.59 million. This growth, a staggering 1,112.5% increase from the previous year, is largely attributed to the successful launch of its drug MYQORZO (aficamten), which is used to treat a specific heart condition. Despite this revenue surge, the company reported an earnings per share (EPS) of -$1.67, slightly missing the forecast of -$1.65. Following these results, RBC Capital and Truist Securities have both raised their price targets for Cytokinetics shares, reflecting positive trends in the company’s market potential.